Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More
X
Scientific presentation

Understanding the power of clonal heterogeneity in health and disease


Aaron Viny, MD, MS
Description

Immunohistochemistry (IHC) has been the gold standard to determine if a patient is in remission, but laboratories are transitioning into RT-PCR for fusions and flow cytometry for greater depth of response. However, clinicians are now moving away from algorithms to understand clonal architecture and mutation acquisition and trying their hand at newer technologies, such as single-cell DNA sequencing. Dr. Viny applies single-cell technology to examine clonal hematopoiesis and minimal residual disease (MRD) to better understand why some mutations are chemosensitive and others resistant to therapy.



VIEW


Scientific presentation
CHIP’ing away at somatic mosaicism — Diving into the promises and challenges of characterizing clonal hematopoiesis of indeterminate potential
Ross Levine, MD
Kelly Bolton, MD, PhD
Jyoti Nangalia, MD, PhD
Todd Druley, MD, PhD
(2022)
Scientific presentation
Meet the Authors: Clonal Heterogeneity in Acute Lymphoblastic Leukemia at Diagnosis and During Chemo Treatment
Jan Cools, PhD, VIB Center for Cancer Biology
(2022)
Scientific presentation
AMP 2021 Corporate Workshop: Single-cell DNA and multi-omics strategies for untangling therapy-resistant mechanisms in oncology
John Lee, M.D., Ph.D., Fred Hutchinson Cancer Research Center & Julia Gouffon, Ph.D., Mission Bio
Association for Molecular Pathology 2021 Digital Experience (2021)
Scientific presentation
Do More Single Cell with Less – Tapestri Platform Expansion for Hematologic Malignancy Research
Koichi Takahashi, MD, PhD, MD Anderson Cancer Center & Jim Flynn, PhD, Mission Bio
(2021)
REQUEST QUOTE